Form 20-F BioNTech SE For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BioNTech (BNTX) PT Lowered to $151 at Truist Securities
March 11, 2025 11:46 AM EDTTruist Securities analyst Asthika Goonewardene lowered the price target on BioNTech (NASDAQ: BNTX) to $151.00 (from $172.00) while maintaining a Buy rating.
The analyst comments "BNTX's reported 4Q24 revenues of 1.19B was ~6% above consensus, but a bigger focus was the FY25 guidance, most notably the significantly... More
Jefferies Reiterates Buy Rating on BioNTech (BNTX)
March 10, 2025 2:23 PM EDTJefferies analyst Akash Tewari reiterated a Buy rating and $149.00 price target on BioNTech (NASDAQ: BNTX).
The analyst comments "Bottom line: BTNX reported an ok Q - Q4 revs ~1.19B vs 1.18B cons & EPS 1.08 vs 0.77 cons driven by lower Opex. That said, BNTX traded down... More
